Valuation dashboard for Envista Holdings Corp (NVST) with P/E 41.28, P/B 1.26, EV/EBITDA 10.41 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures.
Analysis Summary
Envista Holdings Corp reported revenue of $2.72B in the most recent fiscal year, growing at a 5-year CAGR of 7.1%. Net income reached $47.0M, with a 7.1% 5-year CAGR.
Trailing-twelve-month margins: gross margin 55.5%, operating margin 9.9%, net margin 3.3%.
At $23.94 (closing price, October 28, 2026), NVST trades at a P/E of 41.28 and an ROE of 3.08%. Market capitalisation stands at $3.8B.
Balance sheet quality for NVST: current ratio of 2.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 41.28 |
| Price / Book | 1.26 |
| EV / EBITDA | 10.41 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $45.14 |
| vs Current Price | +88.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NVST | Envista Holdings Corp | $3.8B | 41.28 | 1.26 | 3.1% |
| APGE | Apogee Therapeutics, Inc. | $8.4B | 8.53 | -29.9% | |
| ICUI | ICU Medical, Inc. | $4.2B | 141.01 | 1.89 | 1.4% |
| DYN | Dyne Therapeutics, Inc. | $3.2B | 3.99 | -64.3% | |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.4B | 2.33 | -10.4% | |
| PRVA | Privia Health Group, Inc. | $2.8B | 100.69 | 0.00 | 0.0% |
| GRAL | GRAIL Inc. | $5.7B | 2.68 | -15.9% | |
| CON | Concentra Group Holdings Parent, Inc. | $5.2B | 26.36 | 10.78 | 47.3% |
Price
| Price | $23.94 (closing price, October 28, 2026) |
| Market Cap | $3.8B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 3.08% |
| Return on Invested Capital | 2.38% |
| Return on Assets | 1.70% |
| Gross Margin | 55.50% |
| Operating Margin | 9.92% |
| Net Margin | 3.33% |
Related companies: ICUI · DYN · SUPN · PRVA · GRAL · CON
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NVST: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks